Advance your academic career, collaborate globally, and expand your network— join now !

Isabelle Rouiller

Dr. Isabelle Rouiller

Share Link

Share

Information

Isabelle Rouiller is a biochemical engineer who graduated from INSA Lyon in 1994. She completed her PhD in 1998 at the Institute for Animal Health, focusing on the assembly of the African Swine Fever Virus (ASFV) at the Pirbright Laboratories in the UK. Afterward, she pursued postdoctoral training in single-particle cryo-electron microscopy and electron tomography at the Scripps Research Institute and the Burnham Institute in San Diego, USA. In 2007, Isabelle Rouiller established her research group at McGill University in Montreal, Canada, where she conducted cryo-EM studies on medically significant macromolecular complexes. In 2017, she transitioned to the Department of Biochemistry and Pharmacology at the University of Melbourne in Australia. Her current research focuses on conducting structure-function studies of macromolecular complexes using cryo-EM, particularly targeting proteins that show promise for vaccine development as well as those crucial for treating cancer and neurological diseases.

Short Biography

Isabelle Rouiller is a biochemical engineer who graduated from INSA Lyon in 1994. She completed her PhD in 1998 at the Institute for Animal Health, focusing on the assembly of the African Swine Fever Virus (ASFV) at the Pirbright Laboratories in the UK. Afterward, she pursued postdoctoral training in single-particle cryo-electron microscopy and electron tomography at the Scripps Research Institute and the Burnham Institute in San Diego, USA. In 2007, Isabelle Rouiller established her research group at McGill University in Montreal, Canada, where she conducted cryo-EM studies on medically significant macromolecular complexes. In 2017, she transitioned to the Department of Biochemistry and Pharmacology at the University of Melbourne in Australia. Her current research focuses on conducting structure-function studies of macromolecular complexes using cryo-EM, particularly targeting proteins that show promise for vaccine development as well as those crucial for treating cancer and neurological diseases.